Safety of External Electrocardioversion in Device Patients (SEED)
Safety of External Electrocardioversion in Device Patients - the SEED Registry
Arrhythmias of the atria of the heart are a common comorbidity in patients with cardiac rhythm management devices, such as pacemakers and implantable cardioverter/defibrillators (ICD). External electrical cardioversion is an established method to achieve rhythm control (restore normal sinus rhythm) in patients with atrial arrhythmia. Little data on safety and efficacy of external electrical cardioversion in patients with cardiac rhythm management devices exists. Thus, available data on the safety of external electrical cardioversion in cardiac rhythm management patients lacks statistical power to accurately reflect the true hazard of external electrical cardioversion in patients with cardiac rhythm management devices.
The aim is to systematically include and follow all patients with cardiac rhythm management devices presenting for external electrical cardioversion, to analyse the effects of external electrical cardioversion on leads and devices.
調査の概要
詳細な説明
Introduction Atrial arrhythmias are a common comorbidity in patients with cardiac rhythm management (CRM) devices, such as pacemakers and ICD. External electrical cardioversion is an established method to achieve rhythm control in patients with atrial arrhythmia. A paucity of data on safety and efficacy of external electrical cardioversion in patients with cardiac rhythm management devices exists. Most publications are of older date and predominantly case reports or case collections. Few prospective studies with a population of cardiac rhythm management patients after external electrical cardioversion have been published in recent years.
Thus, available data on the safety of external electrical cardioversion in cardiac rhythm management patients lacks statistical power to accurately reflect the true hazard of external electrical cardioversion in patients with cardiac rhythm management devices.
Rationale Electrocardioversion in Propofol sedation for atrial or ventricular tachyarrhythmia is an established therapy. It is routinely used for patients with cardiac rhythm management devices and the risk of device and lead affectation is deemed to be low. This assumption is currently not supported by substantial and current scientific data, mostly relying on older reports. No large, prospective trials with a population of patients with modern cardiac rhythm management devices exists.
Aim of the study The aim is to systematically include and follow all patients with cardiac rhythm management devices presenting for external electrical cardioversion, to analyse the effects of external electrical cardioversion on leads and devices. Thereby, providing reliable evidence and detecting possible SAE with a low incidence. Furthermore, to gather information on efficacy and recurrence rate in this population, to examine the value of external electrical cardioversion for rhythm control in these patients.
研究の種類
入学 (予想される)
連絡先と場所
研究場所
-
-
-
Cologne、ドイツ、50937
- 募集
- University Hospital Cologne
-
コンタクト:
- Daniel Steven, Prof. Dr.
- 電話番号:32396 +49221478
- メール:daniel.steven@uk-koeln.de
-
主任研究者:
- Jakob Lüker, Dr.
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
説明
Inclusion Criteria:
- Age ≥ 18 years
- Informed, written consent
- Atrial or ventricular arrhythmia with indication for CV
- Status post CRM implantation, including CRT-D
Exclusion Criteria:
- Age < 18 years
- Patients under guardianship or with mental disorders / disabilities
- lead implantation < 4 weeks prior to CV
- contraindications for eCV or transoesophageal echocardiographie (TOE)
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 観測モデル:コホート
- 時間の展望:見込みのある
コホートと介入
グループ/コホート |
介入・治療 |
|---|---|
|
Pacemaker patients
Patients with pacemaker, presenting for cardioversion.
|
|
|
ICD patients
Patients with ICD, presenting for cardioversion.
|
|
|
CRT patients
Patients with CRT device, presenting for cardioversion.
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Composite safety endpoint: Changes of lead and device parameters
時間枠:2 weeks after CV
|
assessed by device interrogation, if any of the following criteria is met:
|
2 weeks after CV
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Efficacy Endpoint
時間枠:within 15 minutes after CV
|
Assessed by device interrogation and 12-lead ECG: - restoration of normal sinus rhythm after CV |
within 15 minutes after CV
|
|
Late changes of lead parameters
時間枠:2 weeks after CV
|
Any of the below, assessed by device interrogation:
|
2 weeks after CV
|
|
Inadvertent induction of ventricular fibrillation
時間枠:10 seconds after CV
|
Assessed by 3 lead monitoring ECG
|
10 seconds after CV
|
|
Composite endpoint: Early lead changes
時間枠:within 15 minutes after CV
|
assessed by device interrogation, if any of the following criteria is met:
|
within 15 minutes after CV
|
|
Loss of programming
時間枠:within 15 minutes after CV
|
assessed by device interrogation: - loss of programming of the device |
within 15 minutes after CV
|
|
Change of shock impedance
時間枠:within 15 minutes after CV
|
assessed by device interrogation: - rise in shock impedance by 50% |
within 15 minutes after CV
|
|
Change of charge time
時間枠:within 15 minutes after CV
|
assessed by device interrogation: - rise in charge time by 50% |
within 15 minutes after CV
|
協力者と研究者
捜査官
- 主任研究者:Jakob Lüker, Dr.、University Hospital Cologne
- スタディディレクター:Daniel Steven, Prof. Dr.、University Hospital Cologne
研究記録日
主要日程の研究
研究開始
一次修了 (予想される)
研究の完了 (予想される)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。